Does a High-Risk (>1/50) Result for First-Trimester Combined Screening Always Entail Invasive Testing? Which Patients from This Group Might Benefit from cfDNA Testing?

Currently, cell-free DNA (cfDNA) is offered as part of a contingent screening for patients with a first-trimester combined test (FCT) risk between 1/50 and 1/250. However, most aneuploidies are within the group of patients with a risk above 1/10. An observational, retrospective, and multi-centric st...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Jiménez, Rocío, Valero, Irene, Corrales-Gutiérrez, Isabel, Granell, Reyes, Borrero, Carlota, Sainz-Bueno, José Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599393/
https://www.ncbi.nlm.nih.gov/pubmed/36289845
http://dx.doi.org/10.3390/biomedicines10102579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599393/
https://www.ncbi.nlm.nih.gov/pubmed/36289845
http://dx.doi.org/10.3390/biomedicines10102579

Ejemplares similares